Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.57 |
| ▸ | CDK9 | P50750 | 8/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.57 |
| ▸ | HIPK2 | Q9H2X6 | 6/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.55 |
| ▸ | CDK1 | P06493 | 5/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.55 |
| ▸ | PLK4 | O00444 | 3/20 | 0.55 |
| ▸ | JAK2 | O60674 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | FLT3 | P36888 | 3/20 | 0.55 |
| ▸ | JAK3 | P52333 | 3/20 | 0.55 |
| ▸ | INSR | P06213 | 2/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.55 |
| ▸ | PRKCG | P05129 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8940047 | 0.87 | CDK2 (0.57) | CDK2CDK9CCNT1CCNA2HIPK2 | |
| SCHEMBL11989643 | 0.84 | CDK2 (0.56) | CDK2CDK9CCNT1CCNA2HIPK2 | |
| SCHEMBL1668583 | 0.82 | CDK2 (0.80) | CDK2CDK9CCNT1CCNA2HIPK2 | |
| SCHEMBL8939991 | 0.82 | CDK2 (0.66) | CDK2CDK9CCNT1CCNA2HIPK2 | |
| SCHEMBL2238094 | 0.76 | CDK5 (0.66) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL15172140 | 0.76 | CDK2 (0.70) | CDK2CDK9CCNT1CCNA2HIPK2 | |
| SCHEMBL15172141 | 0.74 | CDK2 (0.68) | CDK2CDK9CCNT1CCNA2HIPK2 | |
| SCHEMBL18942101 | 0.74 | CCNT1 (0.66) | CDK2CDK9CCNT1CCNA2CDK1 | |
| SCHEMBL18942099 | 0.74 | CCNT1 (0.66) | CDK2CDK9CCNT1CCNA2RET | |
| SCHEMBL18942091 | 0.74 | CCNT1 (0.71) | CDK2CDK9CCNT1CCNA2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2786995-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2786995-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2311837-B1 | Azaindoles useful as inhibitors of jak and other protein kinases | VERTEX PHARMA (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2311837-B1 | Azaindoles useful as inhibitors of jak and other protein kinases | VERTEX PHARMA (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2311837-A1 | Azaindoles useful as inhibitors of jak and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311837-A1 | Azaindoles useful as inhibitors of jak and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| EP-1730146-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095400-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | CDK2 23/4885CDK9 85/4885CCNT1 878/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CDK2 23/4885CDK9 85/4885CCNT1 878/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | CDK2 154/4885CDK9 114/4885CCNT1 1640/4885 |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CDK2 23/4885CDK9 85/4885CCNT1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.